The Types segmentation distinguishes storage services by the origin of the immune cells, primarily cord blood-derived, peripheral blood-derived, and combined source offerings. Cord blood-derived cells dominate the market because they are readily available at birth and possess a naïve phenotype, which is highly valued for both basic research and translational applications. Peripheral blood-derived services, though less common, address niche requirements for mature immune cell subsets, supporting late‑stage clinical trials and manufacturing of cell‑based therapeutics. The emerging combined source category integrates multiple neonatal tissues to broaden the repertoire of immune phenotypes, catering to complex research protocols and multi‑antigen therapeutic designs. By aligning storage technology—cryopreservation protocols, quality‑control standards, and biobanking infrastructure—with each cell type, providers can capture distinct revenue streams, reinforcing the market taxonomy and informing strategic resource allocation.